# Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

> **NCT07745361** · PHASE2 · RECRUITING · sponsor: **Monte Rosa Therapeutics, Inc** · enrollment: 25 (estimated)

## Conditions studied

- Castration-Resistant Prostate Cancer (CRPC)
- Castration-Resistant Prostate Cancer
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** Oral MRT-2359
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT07745361
- **Lead sponsor:** Monte Rosa Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-18
- **Primary completion:** 2027-10
- **Final completion:** 2028-04
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07745361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07745361, "Study of Oral MRT-2359 With Apalutamide in Prostate Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07745361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*